CDK inhibition and cancer therapy

Current Opinion in Genetics and Development

Volumn 9, Issue 1, 1999, Pages 104-111

  Garrett, Michelle D ^a   Fattaey, Ali ^a  

^a ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BUTYROLACTONE; CVT 318; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; OLOMOUCINE; PEPTIDE; PURVALANOL; ROSCOVITINE; STAUROSPORINE; SURAMIN; UNCLASSIFIED DRUG;

CANCER; CELL CYCLE; CELL DIVISION; DNA SYNTHESIS; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0032998556     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)80015-X     Document Type: Article

References (111)

1. Morgan DO, Fisher RP, Espinoza FH, Farrell A, Nourse J, Chamberlin H, Jin P Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J Sci Am. 4( ):1998;S77-83.
2. Arellano M, Moreno S Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol. 29:1997;559-573.
3. Lees E Cyclin dependent kinase regulation. Curr Opin Cell Biol. 7:1995;773-780.
4. Morgan DO Principles of CDK regulation. Nature. 374:1995;131-134.
5. Norbury C, Nurse P Animal cell cycles and their control. Annu Rev Biochem. 61:1992;441-470.
6. Elledge SJ Cell cycle checkpoints: preventing an identity crisis. Science. 274:1996;1664-1672.
7. Nasmyth K Viewpoint: putting the cell cycle in order. Science. 274:1996;1643-1645.
8. Nasmyth K At the heart of the budding yeast cell cycle. Trends Genet. 12:1996;405-412.
9. Nurse P, Masui Y, Hartwell L Understanding the cell cycle. Nat Med. 4:1998;1103-1106. A good recent summary (with a historical perspective) on cell-cycle research.
10. Paulovich AG, Toczyski DP, Hartwell LH When checkpoints fail. Cell. 88:1997;315-321.
11. Peeper DS, Bernards R Communication between the extracellular environment, cytoplasmic signalling cascades and the nuclear cell-cycle machinery. FEBS Lett. 410:1997;11-16.
12. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen MG Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 386:1997;177-181. [published erratum appears in Nature 1997 386:521.].
13. Lavoie JN, Rivard N, L'Allemain G, Pouyssegur J A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res. 2:1996;49-58.
14. Aktas H, Cai H, Cooper GM Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 17:1997;3850-3857.
15. Hall M, Peters G Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:1996;67-108.
16. Sherr CJ Cancer cell cycles. Science. 274:1996;1672-1677.
17. Weinberg RA How cancer arises. Sci Am. 275:1996;62-70.
18. Meijer L Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:1996;393-397.
19. Ohashi M, Sugikawa E, Nakanishi N Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res. 86:1995;819-827.
20. Nomoto T, Nishio K, Saijo N Cell cycle regulation by anticancer agent. Gan To Kagaku Ryoho. 22:1995;1719-1723.
21. Rebhun LI, White D, Sander G, Ivy N Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. Exp Cell Res. 77:1973;312-318.
22. Neant I, Guerrier P 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp Cell Res. 176:1988;68-79.
23. Meijer L, Pondaven P Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. Exp Cell Res. 174:1988;116-129.
24. Rialet V, Meijer L A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. Anticancer Res. 11:1991;1581-1590.
25. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc J Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 224:1994;771-786.
26. Schulze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 22:1995;378-391.
27. Havlicek L, Hanus J, Vesley J, Leclerc S, Meijer L, Shaw G, Strnad M Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem. 40:1997;408-412.
28. De Azevedo WF, Lecelrc S, Meijer L, Strnad M, Kim SH Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 243:1997;518-526. The introduction of this report gives an excellent review on inhibition of CDKs by purine-based analogues, followed by biochemical and crystallographic information on roscovitine, one of the more recent members of this family.
29. Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SRet al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 272:1997;29207-29211. This reference provides information on the biochemical and cellular effects of CVT-313, one of the newest purine analogues.
30. Gray NS, Wodicka L, Thunnisen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, Leclerc S, Meijer L Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538. This is the most recent paper on the purine-based class of CDK inhibitors and is interesting in that it describes how chemical libraries, crystallographic data and genomics can be used to identify more potent CDK inhibitors such as purvalanol A and B.
31. Abraham RT, Acquarone M, Andersen A, Aseni A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell. 83:1995;105-120.
32. •] and reports the biochemical and cellular effects of the purine analogue roscovitine.
33. Misteli T, Warren G Mitotic disassembly of the Golgi apparatus in vivo. J Cell Sci. 108:1995;2715-2727.
34. Kwon YG, Lee SY, Choi Y, Greengard P, Nairn AC Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc Natl Acad Sci USA. 94:1997;2168-2173.
35. Hajduch M, Kolar Z, Novotny R, Hanus J, Mihal V, Hlobilkova A, Strnad M Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. Anticancer Drugs. 8:1997;1007-1013.
36. Iseki H, Ko TC, Xue XY, Seapan A, Hellmich MR, Townsend CM Jr. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery. 122:1997;187-194. discussion 194-195.
37. Kitagawa M, Okabe T Ogino H, Matsumoto H, Suzucki-Takahashi I, Kokubo T, Higashi H, Taya Y, Yasuda H Butyrolactone, I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene. 8:1993;2425-2432.
38. Kitagawa M, Higashi H, Takahashi IS, Okabe T, Ogino H, Taya Y, Hisumura S, Okuyama A A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene. 9:1994;2549-2557.
39. Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijon N Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16:1996;3387-3395.
40. Wada M, Hosotani R, Lee JU, Doi R, Koshiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Okuyama A, Imamura M An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res. 18:1998;2559-2566.
41. Yamamoto H, Monden T, Miyoshi H, Izawa H, Ikeda K, Tsujie M, Ohnishi T, Sekimoto M, Tomita N, Monden Met al. Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. Int J Oncol. 13:1998;233-239.
42. Hans Harald Sedlacek JC, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E Glavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 9:1996;1143-1168.
43. De Azevedo WF Jr., Muller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA. 93:1996;2735-2740.
44. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
45. Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintailla-Martinez L, Ensley JF, Sausville EA, Silvio Gutkind J Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 102:1998;1674-1681.
46. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville EA Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 84:1992;1736-1740.
47. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebg HH Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res. 3:1997;273-279.
48. Bible KC, Kaufmann SH Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56:1996;4856-4861.
49. Wright J, Blatner GL, Cheson BD: Clinical trials referral resource. Clinical trials of flavopirido. Oncology 1998, 12:1018,1023-1014.
50. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 16:1998;2986-2999.
51. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 55:1995;3250-3253.
52. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene. 15:1997;2049-2057.
53. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene. 14:1997;2283-2289.
54. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 12:1996;103-110.
55. Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, Kratzke RA Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 16:1998;3087-3095.
56. Sandig V, Brand K, Herwig S, Lukas J, Barlek J, Strauss M Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 3:1997;313-319.
57. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene. 13:1996;1395-1403.
58. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55:1995;5151-5155.
59. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol. 158:1997;636-641.
60. Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, Sartar FH Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas. 16:1998;107-113.
61. Joshi US, Chen YQ, Kalemkerian GP, Adil MR, Kraut M, Sarkar FH Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther. 5:1998;183-191.
62. Katayose D, Wersto R, Cowan KH, Seth P Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ. 6:1995;1207-1212.
63. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo [see comments]. Nat Med. 1:1995;1052-1056.
64. Wang X, Gorospe M, Huang Y, Holbrook NJ p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 15:1997;2991-2997.
65. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57:1997;5441-5445.
66. McConnell BB, Starborg M, Brookes S, Peters G Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol. 8:1998;351-354.
67. Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol. 6:1996;84-91.
68. Fahraeus R, Lain S, Ball KL, Lane DP Characterization of the cyclin dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene. 16:1998;587-596. The most recent paper on the CKI-based peptides that act as CDK inhibitors. These peptides have been linked to a 16 amino acid region of the antennapedia protein of Drosophila, which delivers the peptide inhibitors into live cells so that their cellular activity can be investigated. Interesting technology.
69. Kato D, Miyazawa K, Ruas M, Starborg M, Wada I, Oka T, Sakai T, Peters G, Hara E Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Lett. 427:1998;203-208.
70. Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol. 7:1997;71-80.
71. Bonfanti M, Taverna S, Salmona M, D'Incalci M, Broggini M p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 57:1997;1442-1446.
72. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 380:1996;548-550.
73. van den Heuvel S, Harlow E Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 262:1993;2050-2054.
74. McPherson JP, Goldenberg GJ Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha. Cancer Res. 58:1998;4519-4524.
75. Meikrantz W, Schlegel R Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem. 271:1996;10205-10209.
76. Park DS, Levine B, Ferrari G, Greene LA Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci. 17:1997;8975-8983.
77. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 91:1998;458-465.
78. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 4:1998;2885-2890.
79. Schutte B, Nieland L, Van Engeland M, Henfling ME, Meijer L, Ramaekers FC The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res. 236:1997;4-15.
80. Ongkeko W, Ferguson DJ, Harris AL, Norbury C Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci. 108:1995;2897-2904.
81. Maas JW Jr., Horstmann S, Borasio GD, Anneser JM, Shooter EM, Kahle PJ Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors. J Neurochem. 70:1998;1401-1410.
82. Markus MA, Kahle PJ, Winkler A, Horstmann S, Anneser JM, Borasio GD Survival-promoting activity of inhibitors of cyclin-dependent kinases on primary neurons correlates with inhibition of c-Jun kinase-1. Neurobiol Dis. 4:1997;122-133.
83. Park DS, Morris EJ, Stefanis L, Troy CM, Shelanski ML, Geller HM, Greene LA Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci. 18:1998;830-840.
84. Gervais JL, Seth P, Zhang H Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem. 273:1998;19207-19212.
85. Levkau B, Koyamam H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell. 1:1998;553-563.
86. Park JA, Kim KW, Kim SI, Lee SK Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells. Eur J Biochem. 257:1998;242-248.
87. Zhou BB, Li H, Yuan J, Kirschner MW Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci USA. 95:1998;6785-6790.
88. O'Connor PM, Fan S DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res. 2:1996;165-173.
89. O'Connor PM Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29:1997;151-182.
90. Harper JW, Elledge SJ The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev. 12:1998;285-289.
91. Yao SL, McKenna KA, Sharkis SJ, Bedi A Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1β-converting enzyme-related proteases. Cancer Res. 56:1996;4551-4555.
92. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 88:1996;956-965.
93. Poon RY, Chau MS, Yamashita K, Hunter T The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res. 57:1997;5168-5178.
94. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem. 273:1998;33455-33464.
95. Jin P, Hardy S, Morgan DO Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol. 141:1998;875-885.
96. Jin P, Gu Y, Morgan DO Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol. 134:1996;963-970.
97. Blasina A, Paegle ES, McGowan CH The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells. Mol Biol Cell. 8:1997;1013-1023.
98. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57:1997;1569-1574.
99. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, Warburton D Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol. 273:1997;L941-949.
100. Kornmann M, Arber N, Korc M Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 101:1998;344-352.
101. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, Kaneda Y, Sawa Y, Matsuda H, Ogihara T, Sekiguchi M Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide [see comments]. Nat Med. 3:1997;900-903.
102. Hershko A Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol. 9:1997;788-799.
103. King RW, Deshaies RJ, Peters JM, Kirschner MW How proteolysis drives the cell cycle. Science. 274:1996;1652-1659.
104. Rolfe M, Chiu MI, Pagano M The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med. 75:1997;5-17.
105. Coats S, Flanagan WM, Nourse J, Roberts JM Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 272:1996;877-880.
106. Wang S, Wuu J, Savas L, Patwardhan N, Khan A The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol. 29:1998;1304-1309.
107. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D p27/kip1 expression in human astrocytic gliomas. Neurosci Lett. 234:1997;127-130.
108. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 153:1998;681-687.
109. Guo Y, Sklar GN, Borkowski A, Kyprianou N Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 3:1997;2269-2274.
110. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Darling JR, Roberts JM Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 3:1997;222-225.
111. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.